<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01435993</url>
  </required_header>
  <id_info>
    <org_study_id>114840</org_study_id>
    <secondary_id>2010-022664-12</secondary_id>
    <nct_id>NCT01435993</nct_id>
  </id_info>
  <brief_title>Multiple Doses of Anti-NOGO A in Relapsing Forms of Multiple Sclerosis</brief_title>
  <official_title>A Randomized, Single Blind, Placebo-controlled, Single Ascending Dose/Repeat Dose Cohort Study to Assess Safety, Tolerability, Pharmacokinetics and Immunogenicity of GSK1223249 in Patients With Relapsing Forms of Multiple Sclerosis.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>GlaxoSmithKline</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>GlaxoSmithKline</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will investigate an experimental new drug, GSK1223249 in patients diagnosed with&#xD;
      relapsing forms of multiple sclerosis. The study will specifically investigate safety (vital&#xD;
      signs like heart rate, blood pressure, Magnetic Resonance Imaging (MRI), and other markers of&#xD;
      health from blood samples), tolerability (any side effects that occur, if any), and&#xD;
      pharmacokinetics (how the body processes the drug and how long the drug stays in the blood,&#xD;
      and in cerebro-spinal fluid). The study will also investigate if patients' own immune system&#xD;
      interacts with GSK1223249.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study will be a randomised, placebo-controlled, single-blind (Investigator and Subject),&#xD;
      single and repeat ascending dose protocol, in multiple sclerosis patients. The study is&#xD;
      designed to evaluate the safety, tolerability, pharmacokinetics, and any potential for&#xD;
      immunogenicity of GSK1223249 (a monoclonal antibody raised against Nogo-A), given&#xD;
      intravenously in Multiple Sclerosis patients. The study will also evaluate exploratory&#xD;
      endpoints including para-clinical activity via magnetic resonance imaging, cerebrospinal&#xD;
      fluid pharmacokinetics, and effect of repeat dose administration of GSK1223249 on disability.&#xD;
      Furthermore MS symptoms, such as relapses and individual symptom severity will be closely&#xD;
      monitored.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <start_date type="Actual">September 8, 2011</start_date>
  <completion_date type="Actual">January 23, 2012</completion_date>
  <primary_completion_date type="Actual">January 23, 2012</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety</measure>
    <time_frame>every 2-4 weeks over 7 months</time_frame>
    <description>• Changes in vital signs, ECG monitoring, blood chemistry, haematology, urinalysis, monitoring of AEs and MS relapses (number, incidence, severity)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Cmax values and AUC(0-∞)</measure>
    <time_frame>Pre-dose; 1hr; 6hr; 12hr; 48hr; Day7; Day13; Follow-up</time_frame>
    <description>Profile of Pharamcokinetics</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Immunogenicity of GSK1223249 in MS patients</measure>
    <time_frame>Predose; Day 85; Day169; Day197</time_frame>
    <description>• Presence of antibodies to GSK1223249 to be assessed in serum samples using validated ECL assays.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics of GSK1223249 in cerebro-spinal fluid (CSF) in MS patients</measure>
    <time_frame>Day7; or Day 29; or Day 35; or Day 85</time_frame>
    <description>Measurement of GSK1223249 in CSF</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">3</enrollment>
  <condition>Multiple Sclerosis, Relapsing-Remitting</condition>
  <arm_group>
    <arm_group_label>Active</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>GSK1223249 slow (60 minutes) intravenous infusion</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Saline slow (60 minutes) intravenous infusion</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>GSK1223249</intervention_name>
    <description>Intravenous infusion</description>
    <arm_group_label>Active</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Saline placebo</intervention_name>
    <description>placebo intravenous infusion</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Diagnosed with a relapsing form of MS .&#xD;
&#xD;
          -  Using one of the following ongoing MS treatment strategies, defined as&#xD;
&#xD;
               1. Currently receiving Beta-interferon/Copaxone for treatment of MS and have been&#xD;
                  receiving the current course of therapy for 3 or more months prior to screening,&#xD;
                  OR&#xD;
&#xD;
               2. Not currently receiving disease modifying therapies for treatment of MS, and has&#xD;
                  not received such therapies for at least 3 months prior to screening.&#xD;
&#xD;
          -  Demonstrated clinical activity in 2 years prior to screening, whilst receiving&#xD;
             current/previous treatment regimen or prior to any treatment regimen&#xD;
&#xD;
          -  Expanded Disability Status Scale (EDSS) score ≤6.0 at either the screening or baseline&#xD;
             visit.&#xD;
&#xD;
          -  Male or female between 18 and 60 years of age inclusive, at the time of signing the&#xD;
             informed consent.&#xD;
&#xD;
          -  Body weight equal to or greater than: 50 kilogrammes&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Complications/History of other diseases that may impact on safety of patients enroling&#xD;
             into the study.&#xD;
&#xD;
          -  Liver function test outside normal range for patient population&#xD;
&#xD;
          -  Treatment with methylprednisolone or any other systemic steroid, for a relapse or&#xD;
             otherwise, within 30 days of screening&#xD;
&#xD;
          -  Treatment in the past 6 months with any of the following agents: Fingolimod (Gilenya),&#xD;
             methotrexate, mitoxantrone, azathioprine, or other small molecule immunosuppressants.&#xD;
&#xD;
          -  History of anaphilaxis to protein based therapeutics or mono-clonal antibodies.&#xD;
&#xD;
          -  Positive result for Hapatitis B, HIV, and/or drugs of abuse, or excessive alcohol&#xD;
             consumption.&#xD;
&#xD;
          -  Not able to undergo MRI scanning safely, or Gadolinium (contrast enhancing agents)&#xD;
             during MRI.&#xD;
&#xD;
          -  Other significant infections e.g. Tuberculosis.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>GSK Clinical Trials</last_name>
    <role>Study Director</role>
    <affiliation>GlaxoSmithKline</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Verona</city>
        <state>Veneto</state>
        <zip>37134</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Lørenskog</city>
        <zip>1478</zip>
        <country>Norway</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Italy</country>
    <country>Norway</country>
  </location_countries>
  <removed_countries>
    <country>Germany</country>
  </removed_countries>
  <verification_date>November 2020</verification_date>
  <study_first_submitted>August 25, 2011</study_first_submitted>
  <study_first_submitted_qc>September 15, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 19, 2011</study_first_posted>
  <last_update_submitted>November 20, 2020</last_update_submitted>
  <last_update_submitted_qc>November 20, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">November 24, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Multiple Sclerosis, Secondary-Progressive with relapses</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Multiple Sclerosis</mesh_term>
    <mesh_term>Multiple Sclerosis, Relapsing-Remitting</mesh_term>
    <mesh_term>Sclerosis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

